Decitabine in chronic leukemias

Seminars in Hematology

Volumn 42, Issue SUPPL. 2, 2005, Pages

  Issa, Jean Pierre J ^a   Byrd, John C ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA1 INTERFERON; AZACITIDINE; BUSULFAN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOSINE DERIVATIVE; FLUDARABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RETINOIC ACID; RITUXIMAB; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; EPIGENETICS; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION; METHYLATION; MYELODYSPLASTIC SYNDROME; PATIENT; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW;

EID: 21844443820     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.05.005     Document Type: Article

References (67)

1. S.I. Bearman, F.R. Appelbaum, C.D. Buckner Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 6 1988 1562 1568
2. J.L. Binet, G. Vaugier, G. Dighiero Investigation of a new parameter in chronic lymphocytic leukemia The percentage of large peripheral lymphocytes determined by the Hemalog D. Prognostic significance Am J Med 63 1977 683 688
3. S. Branford, Z. Rudzki, S. Walsh Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood 102 2003 276 283
4. J.C. Byrd, S. Stilgenbauer, I.W. Flinn Chronic lymphocytic leukemia Hematology (Am Soc Hematol Educ Program) 2004 163 183
5. J.C. Byrd, K. Rai, B.L. Peterson Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia An updated retrospective, comparative analysis of CALGB 9712 and CALGB 9011 Blood 105 2005 49 53
6. B.D. Cheson, J.M. Bennett, M. Grever National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia Revised guidelines for diagnosis and treatment Blood 87 1996 4990 4997
7. J. Cortes, H. Kantarjian Advanced-phase chronic myeloid leukemia Semin Hematol 40 2003 79 86
8. J.F. Costello, C. Plass Methylation matters J Med Genet 38 2001 285 303
9. P.E. Crossen, M.J. Morrison Hypermethylation of the M27beta (DXS255) locus in chronic B-cell leukaemia Br J Haematol 100 1998 191 193
10. M. de Lima, F. Ravandi, M. Shahjahan Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias Cancer 97 2003 1242 1247
11. M.W. Deininger, J.M. Goldman, J.V. Melo The molecular biology of chronic myeloid leukemia Blood 96 2000 3343 3356
12. L.F. Diehl, L.H. Karnell, H.R. Menck The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia Cancer 86 1999 2684 2692
13. H. Dohner, S. Stilgenbauer, A. Benner Genomic aberrations and survival in chronic lymphocytic leukemia N Engl J Med 343 2000 1910 1916
14. B.J. Druker Perspectives on the development of a molecularly targeted agent Cancer Cell 1 2002 31 36
15. B.F. Eichhorst, G. Hopfinger, R. Pasold Fludarabine and cyclophosphamide produces a higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of advanced chronic lymphocytic leukemia (CLL) Results of a phase II (CLL4 Protocol) of the German CLL Study Group (GCLLSG) Blood 104 2004 102 (abstr)
16. S. Faderl, H.M. Kantarjian, M. Talpaz Chronic myelogenous leukemia Update on biology and treatment Oncology (Huntingt) 13 1999 169 180
17. I.W. Flinn, M. Grever, D. Neuberg Fludarabine and cyclophosphamide produces a higher complete response rate and more durabel remissions than fludarabine in patients with previously untreated CLL Intergroup Trial E2997 Blood 104 2004 475 (abstr)
18. S. Giralt, M. Davis, S. O'Brien Studies of decitabine with allogeneic progenitor cell transplantation Leukemia 11 suppl 1 1997 S32 S34
19. M.E. Gorre, C.L. Sawyers Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia Curr Opin Hematol 9 2002 303 307
20. M.R. Grever, K.J. Kopecky, C.A. Coltman Fludarabine monophosphate A potentially useful agent in chronic lymphocytic leukemia Nouv Rev Fr Hematol 30 1988 457 459
21. M. Hanada, D. Delia, A. Aiello bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia Blood 82 1993 1820 1828
22. J.G. Herman, F. Latif, Y. Weng Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma Proc Natl Acad Sci U S A 91 1994 9700 9704
23. A. Hochhaus, T. Hughes Clinical resistance to imatinib Mechanisms and implications Hematol Oncol Clin North Am 18 2004 641 656
24. T.P. Hughes, J. Kaeda, S. Branford Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 2003 1423 1432
25. J.P. Issa, G. Garcia-Manero, F.J. Giles Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 2004 1635 1640
26. J.P. Issa, V. Gharibyan, J. Cortes Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate J Clin Oncol 2005 May 9, (Epub ahead of print)
27. A. Jemal, A. Thomas, T. Murray Cancer statistics, 2002 CA Cancer J Clin 52 2002 23 47
28. A.M. John, N.S. Thomas, G.J. Mufti Targeted therapies in myeloid leukemia Semin Cancer Biol 14 2004 41 62
29. S. Johnson, A.G. Smith, H. Loffler Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL Lancet 347 1996 1432 1438
30. H.M. Kantarjian, S.M. O'Brien, M. Keating Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia Leukemia 11 1997 1617 1620
31. H.M. Kantarjian, J. Cortes, S. O'Brien Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase Blood 99 2002 3547 3553
32. H.M. Kantarjian, S. O'Brien, J. Cortes Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia Cancer 98 2003 522 528
33. H. Kantarjian, M. Talpaz, S. O'Brien High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood 103 2004 2873 2878
34. P. Kantharidis, A. El-Osta, M. deSilva Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance Clin Cancer Res 3 1997 2025 2032
35. M.J. Keating, H. Kantarjian, M. Talpaz Fludarabine A new agent with major activity against chronic lymphocytic leukemia Blood 74 1989 19 25
36. M. Keating, S. O'Brien, M. Albitar Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia J Clin Oncol 2005 March 14, (Epub ahead of print)
37. R. Kurzrock, H. Kantarjian, M. Talpaz Chronic myelogenous leukemia in chronic phase Curr Treat Options Oncol 2 2001 245 252
38. M.S. Lee, G. Lowe, S. Flanagan Human Dermo-1 has attributes similar to twist in early bone development Bone 27 2000 591 602
39. M. Leporrier, S. Chevret, B. Cazin Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients Blood 98 2001 2319 2325
40. K. Lin, P.D. Sherrington, M. Dennis Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia Blood 100 2002 1404 1409
41. K. Lin, S. Manocha, R.J. Harris High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment Blood 102 2003 1145 1146
42. V. Lipsanen, P. Leinonen, L. Alhonen Hypomethylation of ornithine decarboxylase gene and erb-A1 oncogene in human chronic lymphatic leukemia Blood 72 1988 2042 2044
43. R. Maestro, A.P. Dei Tos, Y. Hamamori Twist is a potential oncogene that inhibits apoptosis Genes Dev 13 1999 2207 2217
44. J.R. Melki, P.C. Vincent, R.D. Brown Hypermethylation of E-cadherin in leukemia Blood 95 2000 3208 3213
45. R.L. Momparler, J. Bouchard, J. Samson Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2′-deoxycytidine Leuk Res 9 1985 1361 1366
46. S.G. O'Brien, F. Guilhot, R.A. Larson Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004
47. D.G. Oscier, Z. Davis, W. Michaela Zap70 methylation correlates with Zap70 expression in chronic lymphocytic leukemia Blood 104 2004 962 (abstr)
48. G.A. Otterson, S.N. Khleif, W. Chen CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine Oncogene 11 1995 1211 1216
49. K. Peggs, S. Mackinnon Imatinib mesylate - The new gold standard for treatment of chronic myeloid leukemia N Engl J Med 348 2003 1048 1050
50. A. Pinto, V. Attadia, A. Fusco 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias Blood 64 1984 922 929
51. K.R. Rai, A. Sawitsky, E.P. Cronkite Clinical staging of chronic lymphocytic leukemia Blood 46 1975 219 234
52. K.R. Rai, B.L. Peterson, F.R. Appelbaum Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med 343 2000 1750 1757
53. A. Raval, D.M. Lucas, J.J. Matkovic TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia J Clin Oncol 2005 April 4, (Epub ahead of print)
54. F. Ravandi, H. Kantarjian, A. Cohen Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant Results of a phase I study Bone Marrow Transplant 27 2001 1221 1225
55. L.J. Rush, C. Plass Alterations of DNA methylation in hematologic malignancies Cancer Lett 185 2002 1 12
56. L.J. Rush, A. Raval, P. Funchain Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets Cancer Res 64 2004 2424 2433
57. S. Sacchi, H.M. Kantarjian, S. O'Brien Chronic myelogenous leukemia in nonlymphoid blastic phase Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients Cancer 86 1999 2632 2641
58. V. Santini, H.M. Kantarjian, J.P. Issa Changes in DNA methylation in neoplasia pathophysiology and therapeutic implications Ann Intern Med 134 2001 573 586
59. C.L. Sawyers, A. Hochhaus, E. Feldman Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis Results of a phase II study Blood 99 2002 3530 3539
60. N.P. Shah, J.M. Nicoll, B. Nagar Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 2002 117 125
61. M. Talpaz, R.T. Silver, B.J. Druker Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia Results of a phase 2 study Blood 99 2002 1928 1937
62. M. Tamura, M. Noda Identification of DERMO-1 as a member of helix-loop-helix type transcription factors expressed in osteoblastic cells J Cell Biochem 72 1999 167 176
63. M. Tessema, F. Langer, J. Dingemann Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML) Leukemia 17 2003 910 918
64. S. Thijsen, G. Schuurhuis, J. van Oostveen Chronic myeloid leukemia from basics to bedside Leukemia 13 1999 1646 1674
65. J. Wahlfors, H. Hiltunen, K. Heinonen Genomic hypomethylation in human chronic lymphocytic leukemia Blood 80 1992 2074 2080
66. L. Yu, C. Liu, J. Vandeusen Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia Nat Genet 37 2005 265 274
67. M.R. Yuille, A. Condie, E.M. Stone TCL1 is activated by chromosomal rearrangement or by hypomethylation Genes Chromosomes Cancer 30 2001 336 341